| Symbol | SPRC |
|---|---|
| Name | SCISPARC LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20 RAUL WALLENBERG STREET,TOWER A, 2ND FLOOR, TEL AVIV, 6971916, Israel |
| Telephone | +972 37175777 |
| Fax | — |
| — | |
| Website | https://www.scisparc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001611746 |
| Description | SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority. Additional info from NASDAQ: |
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Read moreSciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
Read moreSciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Read moreNew Form F-3/A - SciSparc Ltd. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001213900-26-091651 <b>Size:</b> 304 KB
Read moreNew Form 20-F/A - SciSparc Ltd. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001213900-26-091427 <b>Size:</b> 8 MB
Read moreSciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
Read more